Sagespring Wealth Partners’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$815K Buy
9,449
+1,497
+19% +$125K 0.01% 414
2026
Q2
$536K Sell
7,952
-503
-6% -$33.5K 0.01% 509
2026
Q1
$531K Sell
8,455
-1,853
-18% -$129K 0.01% 482
2025
Q4
$684K Sell
10,308
-129
-1% -$8.34K 0.01% 399
2025
Q3
$702K Sell
10,437
-580
-5% -$45.9K 0.01% 375
2025
Q2
$962K Buy
11,017
+465
+4% +$36.4K 0.02% 290
2025
Q1
$721K Buy
10,552
+5,172
+96% +$422K 0.02% 309
2024
Q4
$418K Buy
+5,380
New +$398K 0.01% 386

Other funds holding DXCM

Sagespring Wealth Partners's DXCM Position: Q3 2026 in Review

Sagespring Wealth Partners increased its DexCom (DXCM) stake by 19% in Q3 2026, buying an estimated $125K and bringing the position to 9,449 shares worth $815K. The position accounts for 0.01% of the portfolio, ranked #414.

Sagespring Wealth Partners first reported a position in DXCM in Q4 2024 and has held it in 8 quarters since. The position peaked at $962K in Q2 2025. 1,038 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Sagespring Wealth Partners held 9,449 shares of DexCom worth $815K as of Q3 2026.
  • Sagespring Wealth Partners bought 1,497 DexCom shares in Q3 2026, an estimated $125K.
  • DexCom made up 0.01% of Sagespring Wealth Partners's portfolio in Q3 2026, its #414 holding.
  • Sagespring Wealth Partners first reported a position in DexCom in Q4 2024 and has held it in 8 quarters since.
  • Sagespring Wealth Partners's DexCom position peaked at $962K in Q2 2025.
  • 1,038 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Sagespring Wealth Partners's 13F filing for Q3 2026, filed 22 Oct 2026.